NEWS

WIRES

OTHER

Emerging Healthcare Solutions Closes $1.8 Million Biotech Funding Commitment

EHSI has agreed to provide funding for operations to Celulas Genetica for up to ten years in exchange for up to 20% of profits to be generated by the company in the future. This investment is vital to enable Celulas Genetica to advance its research for the purpose of finding cures for major diseases. EHSI believes the company will deliver profits many times higher than the amount of its investment in the years ahead. The amount of funding commitment over the term of the Agreement totals $1.8 million.

Celulas Genetica is a stem cell research company working on stem cell research solutions aimed at cures to major diseases and the development of new treatments for researchers and universities in Central and South America. They believe that new stem cell therapies could produce billions of dollars of revenue for the companies that develop these cures and bring them to market. An example of how powerful this business model can be is seen in Pfizer's (NASDAQ: PFE) (the name behind cholesterol-lowering drug Lipitor and erectile dysfunction treatment Viagra) recent licensing of a new stem-cell therapy for inflammatory bowel disease from Athersys (NASDAQ: ATHX).

Celulas Genetica is located next to the John Hopkins University Hospital in booming Panama City, Panama. The company is currently working towards the acquisition of the first stem cell bioreactor to be located in Central America. This should position the company to make real and rapid progress in research aimed at delivering effective cures to major diseases.

Other Biotechnology sector stocks that give context to the significance of the exploding stem cell research industry include ViaCell (NASDAQ: VIAC) and Amgen (NASDAQ: AMGN).

About Emerging Healthcare Solutions, Inc.

Emerging Healthcare Solutions, Inc. invests in and participates in the profits of emerging breakthrough medical technologies. The Company believes the secret of leveraging major future value for its shareholders is the proper timing of its investment in promising new medical technologies. EHSI aims to capture future profits of promising new medical technologies by investing in these technologies at the inflection point of product development. We believe this model will deliver long-term positive results for our investors.

For more information, visit http://www.emerginghealthcaresolutionsinc.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Emerging Healthcare Solutions, Inc.
Kathleen Delaney, 713-821-1486